Related Experiment Video
Updated: Jan 21, 2026

Modulation of Tau Subcellular Localization as a Tool to Investigate the Expression of Disease-related Genes
Published on: December 20, 2019
[Anti-tau therapies-what can be expected?]
Klaus Fließbach1,2, Cornelia McCormick1,2, Barbara Kaulen1,2
1Klinik für Neurodegenerative Erkrankungen und Gerontopsychiatrie, Universitätsklinikum Bonn Venusberg, Campus 1, 53127, Bonn, Deutschland.
New Alzheimer's disease therapies target tau protein, moving beyond amyloid-beta. This review covers advancements in anti-tau immunization and antisense oligonucleotides (ASO) for Alzheimer's treatment.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Alzheimer's disease (AD) is defined by amyloid-beta and tau protein aggregates.
- Early AD interventions focused on amyloid pathology.
- Recent therapeutic strategies target tau pathology.
Purpose of the Study:
- To summarize recent progress in anti-tau therapies for Alzheimer's disease.
- To highlight novel therapeutic approaches targeting tau protein.
Main Methods:
- Review of current research on anti-tau therapies.
- Focus on anti-tau immunization strategies.
- Analysis of antisense oligonucleotides (ASO) for tau reduction.
Main Results:
- Emerging anti-tau therapies show promise in preclinical and clinical studies.
- Anti-tau immunization strategies aim to clear pathological tau species.
- Antisense oligonucleotides (ASO) offer a targeted approach to reduce tau production.
Conclusions:
- Targeting tau pathology represents a promising frontier in Alzheimer's disease treatment.
- Anti-tau immunization and ASO therapies are key areas of development.
- Further research is needed to optimize these tau-centric approaches for AD.
Related Concept Videos
Expected Value
Kendall's Tau Test
A τ value of +1 indicates...
Determination of Expected Frequency
Expected Frequencies in Goodness-of-Fit Tests
Gene Therapy
Group Therapy

